Search
Illinois Paid Clinical Trials
A listing of 2681 clinical trials in Illinois actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
2461 - 2472 of 2681
Illinois is currently home to 2681 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Transcranial Magnetic Stimulation (TMS) for Obsessive Compulsive Disorder (OCD)
Recruiting
Transcranial magnetic stimulation (TMS) is an FDA-approved, non-invasive form of brain stimulation for OCD. TMS has been shown to be an effective form of treatment in individuals with OCD. By using a form of TMS termed theta-burst stimulation (TBS), we hope that this will result in a more effective treatment by producing faster symptom reduction. We are trialing a novel form of accelerated TMS, where we will deliver ten 10-minute sessions per day, for 5 days. This study will compare the efficacy of TMS for OCD at two distinct brain regions. Participants will be randomized into one of two study groups, and receive stimulation at either the DMPFC or R-OFC. Both regions have been linked to OCD by research. Patients that don't respond to their study region will have the option to receive stimulation at the other region.
Conditions:
Obsessive-Compulsive Disorder
Obsessive Compulsive Disorder
Obsessive Compulsive Disorder (OCD)
Obsessive-Compulsive Disorder (OCD)
Obsessive-compulsive Disorders and Symptoms
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? Join this online study from the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Featured Trial
High Triglyceride Clinical Research Study
Recruiting
Living with high triglycerides? See if our clinical study is right for you.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.
Conditions:
High Triglycerides
High Triglyceride Level
Hypertriglyceridemia
Elevated Triglycerides
Triglycerides High
The Gut and Skin Microbiome in Vitiligo Disease Progression
Recruiting
Investigators plan to perform a pilot study that aims to characterize the microbiome of human vitiligo patients with both active and stable disease and compare this to the microbiome of age and sex matched controls. The investigators aim to answer the question whether the gut and skin microbiome of patients with vitiligo differs from the general population.
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
11/07/2023
Locations: Northwestern University, Chicago, Illinois
Conditions: Vitiligo, Healthy
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Recruiting
This is an open-label phase 2/3 study for individuals with Congenital Myotonic Dystrophy (Congenital DM1) who participated in the preceding AMO-02-MD-2-003 study or individuals with either Congenital or Childhood Onset DM1 who are treatment naïve.
Gender:
All
Ages:
Between 6 years and 45 years
Trial Updated:
11/05/2023
Locations: Lurie's Children's Hospital, Chicago, Illinois
Conditions: Congenital Myotonic Dystrophy
Safety and Efficacy Evaluation of the Mosaic Ultra Device
Recruiting
Evaluate the Safety and Efficacy of the Mosaic Ultra 1550nm system for the treatment of skin tone and texture, facial rejuvenation, photoaging, wrinkles, scars, stretch marks, acne vulgaris and hair loss.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
11/01/2023
Locations: Advanced Dermatology, Lincolnshire, Illinois
Conditions: Skin Texture Disorder, Photoaging, Wrinkle, Scar, Stretch Mark, Acne Vulgaris, Hair Loss
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia
Recruiting
A new drug called azeliragon could be used to treat patients with COVID-19 or other pneumonia infections but the researchers don't know. In this study, they are learning the effects of azeliragon patients hospitalized for COVID-19 or pneumonia.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/27/2023
Locations: Rush University, Chicago, Illinois
Conditions: COVID-19
Wool Clothing for the Management of Childhood Atopic Dermatitis (DESSINE2)
Recruiting
The study is a sequentially recruited, cross-over-cohort, outpatient-based evaluation of the effectiveness of wool clothing, as compared to standard clothing, in reducing the severity of childhood atopic dermatitis (eczema) over two consecutive six-week periods.
Gender:
All
Ages:
Between 3 months and 5 years
Trial Updated:
10/26/2023
Locations: Northwestern University, Skin Disease Research Center, Lurie Children's Hospital, Chicago, Illinois
Conditions: Dermatitis, Atopic
Study of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis
Recruiting
This is a pilot study with a 4-period double-cross-over design evaluating a treatment with non-steroidal anti-inflammatory drugs (NSAIDs) in people with painful knee osteoarthritis.
Gender:
All
Ages:
40 years and above
Trial Updated:
10/25/2023
Locations: Northwestern University Feinberg School of Medicine, Chicago, Illinois
Conditions: Osteoarthritis, Knee
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Recruiting
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy at a healthy weight.
This study is being done to find out if caloric restriction achieved by a personalized nutritional menu and exercise plan during routine chemotherapy... Read More
Gender:
All
Ages:
Between 10 years and 25 years
Trial Updated:
10/25/2023
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: B-cell Acute Lymphoblastic Leukemia, Obesity
Using Information Technology to Improve Outcomes for Children Living With Cancer
Recruiting
This proposed study plans to develop and evaluate a patient-oriented, technology-based, symptom monitoring system that reports symptoms experienced by children with cancer to their parents and health care providers.
Gender:
All
Ages:
Between 8 years and 17 years
Trial Updated:
10/25/2023
Locations: Ann & Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois
Conditions: Cancer
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
Recruiting
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an... Read More
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
10/24/2023
Locations: ACTION3 Investigational Site 15, Evanston, Illinois
Conditions: FSGS
Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial
Recruiting
The objective of the PORTICO pivotal IDE trial is to evaluate the safety and effectiveness of the St Jude Medical (SJM) Portico Transcatheter Heart Valve and Delivery Systems (Portico) in the treatment of severe symptomatic aortic stenosis via transfemoral and alternative delivery methods in high risk and extreme risk patients.
Gender:
All
Ages:
21 years and above
Trial Updated:
10/24/2023
Locations: Advocate Christ Medical Center, Oak Lawn, Illinois
Conditions: Aortic Valve Stenosis
Outcomes of Irrisept Irrigation as an Adjunctive Treatment in the Management of Diabetic Foot Ulcers
Recruiting
Irrisept™ irrigation containing Chlorhexidine Gluconate (CHG) 0.05% in sterile water, is an irrigation method that may help reduce bacterial load considerably more than traditional saline irrigation.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: Northern Illinois Foot & Ankle Specialists, Cary, Illinois
Conditions: Diabetic Foot Ulcer
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
Recruiting
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
10/17/2023
Locations: IMA Research, Inc., Chicago, Illinois
Conditions: Gout, Hyperuricemia, Gout Flare, Tophi